Our CEO, Amnon Kritzman Kadron, participated in the last DDL (Drug Delivery to the Lungs) conference that took place in Edinburg, UK
An article by the name “The Great Why Questions About Dry Powder Inhalers”, written by Amnon, was published in the INTERNATIONAL PHARMACEUTICAL INDUSTRY journal.
Our CEO, Amnon Kritzman Kadron, took part in the forum in Cambridge, UK.
We are delighted to share exciting news following our participation at the BioMed 2023 conference in Tel Aviv, Israel!
CanDapi made a significant impact by showcasing our revolutionary Vibrating Mesh™ Technology, single and multi-use Dry Powder Inhaler (DPI) device, used to deliver medications to the lungs in the form of a dry powder.
Moreover, we are delighted to announce that our team had the privilege of conducting successful meetings with international investors and potential customers during the conference. These productive discussions have laid the foundations for potential partnerships and collaborations that will further advance the accessibility and efficiency of inhaled medication delivery.
The interest and enthusiasm from the investors we’ve met is a testament to the dedication and hard work of our team in developing a game-changing solution for respiratory medicine.
We would like to express our gratitude to all those who visited our booth, engaged in insightful conversations, and expressed interest in partnering with CanDapi. Your support and enthusiasm fuel our drive to continue pushing the boundaries of innovation in healthcare.
Stay tuned for more updates as we move forward with these exciting opportunities and make a lasting impact on the lives of patients worldwide.
A very encouraging article about the CanNegev startup incubator was published on “HaAretz” newspaper.